World Vaccine Congress Europe 2026 has ended. This guide stays up as the record of who was there. Next: WVC Europe 2027, Oct 25–27, 2027 in Lyon
Infectious disease and AMR at World Vaccine Congress Europe 2026
Oct 19–21, 2026 Amsterdam, Netherlands ~2k attendees Website
91 organizations at World Vaccine Congress Europe 2026 present work in infectious disease & AMR: 39 vaccine and drug developers, 18 public-health and non-profit bodies, 18 suppliers and service providers and 16 academic bodies. Between them they bring 177 presentations to the program. Most represented: Sanofi, GSK and University of Oxford. As of Oct 12, 2026.
All 268 organizations at World Vaccine Congress Europe 2026 →
| Organization | World Vaccine Congress Europe 2026 Attendance |
|---|---|
Sanofi Paris, France | |
Global pharmaceutical company with a large vaccines business spanning influenza, pediatric, meningitis and mRNA programs. | Talk Mon Oct 19 11:30 Talk Mon Oct 19 14:45 Talk Mon Oct 19 15:30 Talk Tue Oct 20 09:00 The Technology Revolution: Agility for the Wave of Next Generation Vaccines Which newer vaccine platforms, such as RNA, could shorten outbreak response times and extend vaccines to cancer and autoimmune disease. Platforms & delivery Talk Wed Oct 21 12:45 Panel: From Bottleneck to Breakthrough: Reengineering Vaccine Clinical Development Why vaccine development has slowed back to pre-pandemic speeds and which changes, including AI, could make clinical trials faster. Talk Wed Oct 21 13:30 Talk Wed Oct 21 15:00 Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling Whether models built from manufacturing and early trial data can shrink vaccine trials, and what evidence regulators need to trust them. |
GSK London, United Kingdom | |
Panel Mon Oct 19 12:15 Talk Mon Oct 19 15:00 Panel: Global Vaccine Access: Balancing Speed and Safety How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks. Panel Wed Oct 21 10:45 Panel: Emerging Outbreaks at the Front Line: From Early Signals to Real-World Response How outbreaks like bird flu and hantavirus can be spotted sooner, what vaccines add to the response, and where gaps remain. Talk Wed Oct 21 13:15 Panel Wed Oct 21 14:30 Panel: Can TB vaccines deliver on the promise? What tuberculosis vaccine trials can learn from COVID-19, flu and respiratory syncytial virus, and how to make tuberculosis a funding priority. Talk Wed Oct 21 15:00 Panel: Designing Better Vaccine Trials: The Role and Reality of Modelling Whether models built from manufacturing and early trial data can shrink vaccine trials, and what evidence regulators need to trust them. | |
University of Oxford Oxford, UK | |
Talk Mon Oct 19 10:00 Talk Mon Oct 19 11:45 Talk Tue Oct 20 16:30 Panel Tue Oct 20 17:00 One Health in Action: Connecting Human, Animal, and Environmental Health to Advance Vaccine Strategy How tracking disease in people, animals and the environment together can set vaccine priorities for infections that jump from animals, like bird flu. One Health & ecosystems Talk Wed Oct 21 10:30 Panel Wed Oct 21 10:45 Panel: Emerging Outbreaks at the Front Line: From Early Signals to Real-World Response How outbreaks like bird flu and hantavirus can be spotted sooner, what vaccines add to the response, and where gaps remain. | |
Moderna Cambridge, MA | |
Talk Mon Oct 19 14:00 Talk Mon Oct 19 15:00 Panel: Global Vaccine Access: Balancing Speed and Safety How regulators worldwide can speed vaccine approval, for example by relying on other agencies' reviews, without weakening safety checks. Talk Mon Oct 19 15:15 Talk Mon Oct 19 16:15 Panel: From Early Signals to Decisions: The Future of Outbreak Intelligence How genome sequencing, wastewater testing and health records can flag outbreaks early enough to guide vaccine strain choice and policy. Talk Tue Oct 20 10:15 One Shot, Many Frontiers: Combination Vaccines for a Healthier Lifetime Whether combining several vaccines into one shot raises coverage at every age, and how to keep such shots safe, effective and widely available. Infectious disease & AMR Talk Wed Oct 21 15:15 | |
IAVI New York, NY | |
Non-profit research organization developing vaccines and antibodies for HIV, tuberculosis and emerging infectious diseases. | Talk Mon Oct 19 11:30 Talk Mon Oct 19 11:45 Panel Mon Oct 19 12:15 Session Wed Oct 21 10:30 Session Wed Oct 21 12:15 Panel Wed Oct 21 13:15 Panel: Rethinking AMR Priorities: Choosing the Targets That Move the Needle How to choose which drug-resistant bacteria to target with vaccines and antibody drugs, using cost-effectiveness models to line up funders and drugmakers. Panel Wed Oct 21 14:30 Panel: Can TB vaccines deliver on the promise? What tuberculosis vaccine trials can learn from COVID-19, flu and respiratory syncytial virus, and how to make tuberculosis a funding priority. |
PATH Seattle, WA | |
Global health non-profit working on vaccine development, delivery and immunization systems in low- and middle-income countries. | Talk Mon Oct 19 16:15 Panel: From Early Signals to Decisions: The Future of Outbreak Intelligence How genome sequencing, wastewater testing and health records can flag outbreaks early enough to guide vaccine strain choice and policy. Talk Mon Oct 19 16:30 Talk Mon Oct 19 16:45 Talk Tue Oct 20 10:15 One Shot, Many Frontiers: Combination Vaccines for a Healthier Lifetime Whether combining several vaccines into one shot raises coverage at every age, and how to keep such shots safe, effective and widely available. Infectious disease & AMR Talk Wed Oct 21 12:00 Working Group: The way forward: how do we ensure that the priority combination vaccines are developed, licensed and used? How a new framework ranks which combination vaccines for children matter most, and how to get those vaccines developed, approved and used. Supply, safety & access Talk Wed Oct 21 12:45 Panel: From Bottleneck to Breakthrough: Reengineering Vaccine Clinical Development Why vaccine development has slowed back to pre-pandemic speeds and which changes, including AI, could make clinical trials faster. Panel Wed Oct 21 13:15 Panel: Rethinking AMR Priorities: Choosing the Targets That Move the Needle How to choose which drug-resistant bacteria to target with vaccines and antibody drugs, using cost-effectiveness models to line up funders and drugmakers. |
Find buyers in infectious disease & AMR
Tell us what you sell and we’ll find the people at organizations working on infectious disease & AMR most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse World Vaccine Congress Europe 2026 by
Not affiliated with or endorsed by the World Vaccine Congress or its organizers. Submit a correction